Stay updated on Pembrolizumab Combo in Metastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0, while the study record continues to show a 403 Forbidden error.
    Difference
    0.3%
    Check dated 2026-10-31T23:14:14.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The clinical trial record for pembrolizumab plus epacadostat versus pembrolizumab plus placebo in metastatic non-small cell lung cancer is now displayed. It includes study design and results measures, participant criteria, international locations, record dates, and study documents.
    Difference
    99%
    Check dated 2026-10-24T23:13:18.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.1 to v3.7.2; the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-17T23:33:14.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page’s footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T23:21:41.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The study page now returns a 403 Forbidden error, blocking access to the study record and its documents. The visible layout shows a 403 message with header and footer, replacing the expected study content.
    Difference
    18%
    Check dated 2026-09-19T22:21:07.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The page now includes related topics metadata (Lung cancer and MedlinePlus Genetics) to help users access background information from linked resources.
    Difference
    0.1%
    Check dated 2026-09-12T19:19:34.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Metastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.